stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Net income
ImmunityBio, Inc.'s net income for fiscal 2025 was −$351.5M, compared with −$413.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$992.4M. Over the past ten years it has ranged from −$583.9M (fiscal 2023) to −$96.2M (fiscal 2018); the current reading is higher than 36% of that period. ImmunityBio, Inc. ranks 601st of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$351.5M | — |
| FY2024 | −$413.6M | — |
| FY2023 | −$583.9M | — |
| FY2022 | −$417.3M | — |
| FY2021 | −$349.8M | — |
| FY2020 | −$224.2M | — |
| FY2019 | −$160.2M | — |
| FY2018 | −$96.2M | — |
| FY2017 | −$96.4M | — |
| FY2016 | −$120.8M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$230.4M | — |
| Mar 2026 | −$632.8M | — |
| Dec 2025 | −$62.0M | — |
| Sep 2025 | −$67.3M | — |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TGTX TG Therapeutics, Inc. compare | $441.5M |
| KRYS Krystal Biotech, Inc. compare | $225.2M |
| CAI Caris Life Sciences,�Inc. compare | $96.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $82.9M |
| TWST Twist Bioscience Corporation compare | −$136.7M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$155.5M |
| SYRE Spyre Therapeutics, Inc. compare | −$263.9M |
| CYTK Cytokinetics, Incorporated compare | −$777.9M |
| IBRX ImmunityBio, Inc. | −$992.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on IBRX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement